EBITDA Margin % is calculated as EBITDA divided by its Revenue. PhoenixBio Co's EBITDA for the
six
months ended in Mar. 2026 was 円136 Mil. PhoenixBio Co's Revenue for the
six
months ended in Mar. 2026 was 円809 Mil. Therefore, PhoenixBio Co's EBITDA margin for the quarter that ended in Mar. 2026 was 16.80%.
PhoenixBio Co (TSE:6190) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PhoenixBio Co EBITDA Margin % Related Terms
PhoenixBio Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PhoenixBio Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6190 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, PhoenixBio Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhoenixBio Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhoenixBio Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PhoenixBio Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PhoenixBio Co (TSE:6190) has a EBITDA Margin % of 16.80% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PhoenixBio Co and its competitors. According to the industry distribution chart, PhoenixBio Co ranks #231 out of 944 companies in the Biotechnology industry, placing it in the top 24.5%.
Is PhoenixBio Co's EBITDA Margin % too high?
PhoenixBio Co's current EBITDA Margin % is 16.80%. Based on the distribution chart, PhoenixBio Co ranks #231 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PhoenixBio Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PhoenixBio Co ranks #231 out of 944 companies for EBITDA Margin %. This places PhoenixBio Co in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PhoenixBio Co and its competitors. PhoenixBio Co's current EBITDA Margin % is 16.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Modestly Undervalued. The stock's GF Value™ is 円361.16, compared to a current price of 円324.00 — trading 10.3% below its estimated fair value. The current EBITDA Margin % is 16.80%. PhoenixBio Co's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current EBITDA Margin % is 16.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhoenixBio Co (TSE:6190) Overvalued in 2026?
Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued.
The current stock price of 円324.00 is trading 10.3% below its estimated GF Value™ of 円361.16.
GuruFocus considers PhoenixBio Co to be Modestly Undervalued.
Key valuation signals for TSE:6190:
EBITDA Margin %: 16.80%
GF Value™: 円361.16 vs. price of 円324.00 (10.3% below fair value)
No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
62GF Score
Get the complete analysis for TSE:6190
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6190 has been successfully added to your 
